Kendle said that its India operations provide customers access to the full spectrum of early and late stage clinical development services conducted by staff experienced in running all phases of trials across all therapeutic areas.
Candace Kendle, chairman and CEO of Kendle International, said: “Expansion in the Asia-Pacific region, and India in particular, is essential to our continued success as a top global clinical research organization. Our increased presence and capacity in the region will allow us to better meet the needs of our customers who are seeking to capitalize on India’s cost-effective, yet high-quality clinical research capabilities to develop their compounds.”